GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » EPS without NRI

Catalyst Biosciences (Catalyst Biosciences) EPS without NRI : $-0.62 (TTM As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences EPS without NRI?

Catalyst Biosciences's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.62.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 43.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 26.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Catalyst Biosciences's EPS without NRI or its related term are showing as below:

CBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -149.4   Med: 38.5   Max: 93.1
Current: 43

During the past 13 years, Catalyst Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 93.10% per year. The lowest was -149.40% per year. And the median was 38.50% per year.

CBIO's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.45 vs CBIO: 43.00

Catalyst Biosciences's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.38.

Catalyst Biosciences's EPS (Basic) for the three months ended in Sep. 2023 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.38.


Catalyst Biosciences EPS without NRI Historical Data

The historical data trend for Catalyst Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences EPS without NRI Chart

Catalyst Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.67 -4.60 -2.93 -2.87 -0.81

Catalyst Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.40 -0.11 -0.07 -0.04

Competitive Comparison of Catalyst Biosciences's EPS without NRI

For the Biotechnology subindustry, Catalyst Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Biosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's PE Ratio without NRI falls into.



Catalyst Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalyst Biosciences  (NAS:CBIO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Catalyst Biosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Biosciences (Catalyst Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Executives
Han Ying director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu director, officer: Chief Executive Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma director, officer: President 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye officer: Chief Operating Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen officer: Interim CFO 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc. 10 percent owner 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller officer: SVP Finance; Interim CFO & PAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd 10 percent owner 12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd. 10 percent owner NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling director 17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo director NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023